Impact of Precision Medicine in Moderate-to-Severe Asthma: Opportunities for Managed Care

Learn About:

1. How T2 inflammation plays a central role in asthma pathophysiology
2. Assess payer care management initiatives to improve patient access and quality of care
3. Assess payer care management initiatives to improve patient access and quality of care

Expert Faculty Presenters:

Dana McCormick, RPh, FAMCP Senior Director, Pharmacy Advisory Services Optum Insights Click here for biography Anju T. Peters, MD, MSCI, FAAAAI Professor of Medicine Director of Clinical Research Division of Allergy/Immunology and Otolaryngology Northwestern University Feinberg School of Medicine Click here for biography De De Gardner, DrPH, RRT, RRT-NPS, FAARC, FCCP Chief Research Officer Allergy & Asthma Network Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
Asthma represents a therapeutic area of significant interest for managed care professionals, and there remains an unmet need to provide comprehensive care for patients with moderate-to-severe asthma. Due to the significant disease burden associated with the disease, the vast majority of managed care plans have implemented chronic care management programs for asthma. Managed care professionals are in a unique position to guide and positively influence the practice of providers in terms of individualized asthma management; this represents a critical step towards the optimization of patient care and treatment outcomes.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe how T2 inflammation plays a central role in asthma pathophysiology and common comorbidities
• Summarize safety, efficacy, and long-term data for biologics used to manage patients with moderate-to-severe asthma
• Assess payer care management initiatives and other opportunities to improve patient access and quality of care based on current evidence from clinical trials, real-world experience, and treatment guidelines

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Continuing Medical Education
PACE designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

UAN: JA4008073-9999-24-175-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.